New Alzheimer’s Drug Approved in USA
US regulators have approved Biogen's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease, sending its shares soaring, despite controversy over whether the clinical evidence proves the drug works.
Biogen said it has priced the drug, to be sold as Aduhelm, at $56,000 per year. Its shares jumped nearly 52% to $434.52 when trading resumed following the approval. US-traded shares of partner Eisai Co were already up $33.50, or 45%, to $107.75
However, cautioned Dr Ronald Petersen, an Alzheimer's disease expert at the Mayo Clinic, "This is not a cure. It's hoped that this will slow the progression of the disease."
Alzheimer's is the sixth-leading cause of death in the United States.
Research and Markets carries the best reports for Alzheimer’s-related treatment below:
We will help you find what you are looking for.